The clinical performance is complex and often involves multi-systemic burdens. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can assist in matching the needs of a team of authoritative experts at home and abroad to provide accurate diagnostics and treatment regimens. The individualized development of treatment regimens for the treatment and management of Erdheim-Chester disease typically includes drug therapy, rehabilitation interventions, regular follow-up. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved.
Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to changes in disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of Erdheim-Chester disease. The platform serves a team of internationally authoritative experts at home and abroad in the field of blood tumours.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.